<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696160</url>
  </required_header>
  <id_info>
    <org_study_id>NEAT44</org_study_id>
    <nct_id>NCT03696160</nct_id>
  </id_info>
  <brief_title>The Late Presenter Treatment Optimisation Study</brief_title>
  <acronym>LAPTOP</acronym>
  <official_title>An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NEAT ID Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NEAT ID Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare two different types of HIV treatments, in terms
      of effectiveness and improvement of side effects, for patients who are diagnosed with a more
      advanced HIV infection. Patients with advanced HIV infections are otherwise known as 'late
      presenters'.

      There are many effective treatments for HIV available; however, for late presenting patients
      the investigators do not know which type of treatment performs best. This is the first large
      study to compare treatments for patients in this situation, and the investigators hope that
      the results of this study will help doctors decide which treatments to use in the future.

      The two different types of treatment the investigators are comparing both contain a mixture
      of drugs that work together to combat HIV:

      The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing:
      darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in
      Europe under the brand name Symtuza®.

      The Integrase Inhibitor combination (INI). Which is a combination tablet containing:
      bictegravir, emtricitabine and tenofovir alafenamide. This is a a newer combination which was
      approved for use in Europe in June 2018 under the brand name of Biktarvy®.

      The main difference between the two treatments is how each one fights a HIV infection. They
      both stop a part of the virus from working (i.e. inhibit it), to prevent it from making
      copies of itself. The PI treatment contains drugs to stop the protease part of the virus,
      whereas the INI treatment contains drugs to stop the integrase part.

      In recent studies, it appears that treatments containing integrase inhibitors may be better
      for late presenting patients. They have been shown to quickly bring down the amount of virus
      in the body, and the side effects may be more acceptable to late presenters.

      To compare the two treatments, half of the participants on this study will be given the PI
      treatment, and the other half will be given the INI treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness of HIV antiretroviral therapy (ART) has consistently improved over the
      years. This is largely due to newer drugs having improved antiviral effectiveness and more
      tolerable side effect profiles; resulting in better viral suppression and improved treatment
      adherence. On the other hand, most recent clinical trials look at the effectiveness of ART in
      patients with less advanced disease. These patients usually suffer from less related
      diseases, drug-drug interactions, and other risks for treatment failure. Outside of these
      trials, the number of patients who present to clinic with a more developed advanced HIV
      infection, known as 'late presenters', remains high across Europe. Trials for these patients
      have tended to focus on the time of starting treatment and the management of infections.

      Much less is known about which ART treatments perform best for these late presenting
      patients; particularly in terms of virus suppression, immune system recovery, side effects
      and improvement of AIDs related diseases. No specific drug combinations have been compared in
      appropriate clinical trials before, and the international guidelines for first line treatment
      judge all therapies as equal standard of care for these patients.

      The investigators anticipate that Integrase inhibitor containing regimes may be better suited
      to patients with advanced disease, due to their beneficial side-effect profile and ability to
      rapidly decrease viral load levels. Therefore the investigators are conducting this clinical
      trial to compare an integrase inhibitor regime, against a protease inhibitor regime in
      patients with advanced HIV infection. The aim of the study is to demonstrate the
      non-inferiority of Biktarvy® against Symtuza®.

      Patients will be recruited from sites across Europe, and randomized onto either arm of the
      study. After randomisation onto either treatment regime, patients will attend approximately 9
      follow-up visits over the course of a year. During these visits, patients will be asked to
      complete two questionnaires, to assess their quality of life and HIV symptoms. They will also
      be asked to provide a number of blood samples. These samples are to ensure that the patient
      is not resistant to the study drug and that their disease is not worsening. Samples to test
      for study drug resistance will be shipped to a laboratory for analysis in the even that the
      patient experiences virological failure.

      Biktarvy® will be supplied from Gilead and Symtuza® will be provided by Janssen
      Pharmaceuticals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Earliest at 12 weeks, latest 48 weeks</time_frame>
    <description>Composite outcome: time to treatment failure due to either virological or clinical reasons. Virological reasons can either be insufficient virological response or viral rebound. Clinical reasons can be death related to HIV/AIDS/opportunistic infection or severe bacterial infection, new or recurrent AIDS defining event, any serious non-AIDS defining event or clinically relevant adverse events of any grade or immune reconstitution inflammatory syndrome requiring treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HIV-RNA viral load &lt;50 copies/mL</measure>
    <time_frame>Week 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 drug resistance confirmed</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach CD4 (cluster of differentiation 4) count &gt;200/µL</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4/CD8 (cluster of differentiation 8) ratio</measure>
    <time_frame>Week 4, 8, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Immune Reconstitution Inflammatory Syndrome</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of hospitalisation or rate of relapse of specific opportunistic or bacterial infection</measure>
    <time_frame>Week 48</time_frame>
    <description>Start/Stop of hospitalization for any reason Start/Stop of opportunistic infections as listed within Appendix 3 (AIDS defining events according to https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm) Start/Stop of severe BI, which consists of any of bacterial pneumonia, invasive bacterial infection (IBI) or any bacterial infectious disorder with grade 3 severity or requiring unscheduled hospital admission. An IBI is defined as the isolation of a bacterial organism from a normally sterile body site, or for bacterial nucleic acid to be detected at a normally sterile body site. Sterile body sites include blood, cerebrospinal fluid, pleural fluid, pericardial fluid, peritoneal fluid, joint fluid, bone aspirate, or a deep tissue abscess.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by Division of AIDS Adverse Event (AE) Grading Table Corrected Version 2.1-July 2017</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral therapy and opportunistic or bacterial infection treatment changes and dose modifications due to toxicities and drug-drug interaction with antiretroviral therapy, and Immune Reconstitution Inflammatory Syndrome</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resource use, including total inpatient days and emergency room visits</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire outcomes</measure>
    <time_frame>Week 48</time_frame>
    <description>EQ-5D-3L (European Quality of life - 5 Dimensions - 3 Levels) questionnaires will be completed by patients throughout the study to assess any change throughout their treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation or modification of study medication due to insufficient virological response or resistance mutation development</measure>
    <time_frame>Week 48</time_frame>
    <description>Discontinuation or modification of the single tablet regimen due virological reasons defined as a) Insufficient virological response, either:
HIV-1 RNA reduction &lt; 1 log 10 copies/mL at week 12, or
Viral load &gt; 50 HIV-1 RNA copies/mL at week 48 b) Viral rebound, which is subsequently confirmed at the following scheduled or unscheduled visit, defined as either:
a. Rebound of HIV-1 RNA to &gt;200 copies/mL after having achieved HIV-1 RNA &lt;50 copies/mL b. Rebound of HIV RNA by &gt;1 log 10 copies/mL from nadir value, for patients whose viral load has never been suppressed below 50 copies/mL</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mutations detected by deep sequencing compared with those detected by population sequencing</measure>
    <time_frame>Week 48</time_frame>
    <description>The resistance associated mutations in genes encoding the reverse transcriptase, protease and integrase of HIV as detected by ultra-deep sequencing and sanger sequencing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with HIV-RNA viral load &lt; 50 copies/mL</measure>
    <time_frame>Week 4, 8, 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Biktarvy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bictegravir is an inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection.
Biktarvy® received marketing authorisation valid throughout the European Union (EU) in June 2018.
Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir (B/F/TAF).
Method of administration: One combined B 50mg/F 200mg/TAF 25mg tablet taken orally once daily for up to 48 weeks without regard to food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symtuza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection.
Symtuza® received marketing authorisation valid throughout the EU in September 2017.
Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)
Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biktarvy</intervention_name>
    <description>Integrase inhibitor used to treat HIV-1 infection</description>
    <arm_group_label>Biktarvy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symtuza</intervention_name>
    <description>Protease inhibitor used to treat HIV-1 infection</description>
    <arm_group_label>Symtuza</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The ability to understand and sign a written informed consent form (ICF) and must be
             willing to comply with all study requirements.

          2. Male or non-pregnant, non-lactating females.

          3. Age ≥ 18 years.

          4. Has documented, untreated HIV-1 infection with either:

               1. AIDS with any CD4 cell count (AIDS-defining conditions are listed within Appendix
                  3).

                  Or

               2. Severe bacterial infection (BI) and must have a CD4 cell count &lt; 200/µl within 30
                  days prior to study entry.

                  Or

               3. Are asymptomatic with CD4 cell count &lt; 100/µL within 30 days prior to study entry
                  and must have an entry HIV viral load &gt; 1000 copies/mL.

                  Or

               4. Currently receiving treatment for opportunistic infection (OI) i. Subjects with
                  other serious OIs, including other AIDS-defining and AIDS-related OIs for which
                  appropriate therapy other than ART exists are eligible, but Investigator approval
                  must be obtained.

             ii. Current OI treatment must have been started ≤ 14 days prior to study entry, but
             can have been discontinued prior to study entry.

          5. Have the ability to take oral medications.

          6. If female and of childbearing potential, is using effective birth control methods (see
             Appendix 7) and is willing to continue practising these birth control methods during
             the trial and for at least 30 days after the last dose of study medication. Note:
             Non-childbearing potential is defined as either post-menopausal (12 months of
             spontaneous amenorrhoea and ≥45 years) or physically incapable of becoming pregnant
             with documented tubal ligation, hysterectomy or bilateral oophorectomy.

          7. If a heterosexually active male, is using effective birth control methods and is
             willing to continue practising these birth control methods during the trial and for at
             least 30 days after the last dose of study medication.

        Exclusion Criteria:

          1. Any antiretroviral prior to study entry.

          2. Systemic cancer chemotherapy within 30 days prior to study entry, or current treatment
             for cancer (with the exception of Kaposi's sarcoma) or lymphoma.

          3. Current or anticipated use of contraindicated medications (see Summary of Product
             Characteristics (SmPC) for Symtuza® and Investigator's Brochure (IB) for Biktarvy®) or
             anticipated systemic chemotherapy during study enrolment (administration of any
             contraindicated medication must be discontinued at least 30 days prior to the baseline
             visit and for the duration of the study).

          4. Known resistance to the components of study medications (see section 6.1.3 for more
             details).

          5. History or symptoms of advanced renal and/or hepatic impairment. Such as, kidney
             failure requiring dialysis; eGFR (epidermal growth factor receptor) &lt;30 mL/min;
             hepatic transaminases (AST and ALT) &gt; 5 x upper limit of normal (ULN); or, platelet
             count &lt;50,000.

          6. Current drug or alcohol use that, in the opinion of the Investigator, would cause
             interference with the study.

          7. Cryptococcal meningitis or active tuberculosis (TB) or current or expected treatment
             requiring Rifampicin or Rifabutin (patients with expected latent TB will have a TB
             test (IGRAs e.g. ELISPOT, QuantiFERON etc.) at their screening visit).

          8. History or presence of allergy to the study drugs or their components, or drugs of
             their class.

          9. Using any concomitant therapy disallowed as per the reference safety information (RSI)
             and product labelling for the study drugs.

         10. Any investigational drug within 30 days prior to the study drug administration.

         11. Patients with severe (Child Pugh class C) hepatic impairment.

         12. Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during
             the study.

         13. Females of childbearing potential and heterosexually active males must be willing to
             use a highly effective method of contraception. See Appendix 7 for further details.
             Such methods include:

             a. combined (oestrogen and progestogen containing) hormonal contraception associated
             with inhibition of ovulation:

             i. oral

             ii.intravaginal

             iii.transdermal

             b.progestogen-only hormonal contraception associated with inhibition of ovulation

             i.oral

             ii. injectable

             iii.implantable

             c. intrauterine device (IUD)

             d. intrauterine hormone-releasing system (IUS)

             e. bilateral tubal occlusion

             f. vasectomised partner

             g. sexual abstinence (with male partners)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Behrens</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LAPTOP Project Manager</last_name>
    <phone>+44 203 859 7747</phone>
    <email>laptop@rokcservices.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LAPTOP Project Manager</last_name>
    <phone>+44 203 859 7747</phone>
    <email>laptop@neat-id.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Tropical Medicine</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Florence</last_name>
    </contact>
    <investigator>
      <last_name>Eric Florence</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephane De Wit</last_name>
    </contact>
    <investigator>
      <last_name>Stephane De Wit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linos Vandekerckhove</last_name>
    </contact>
    <investigator>
      <last_name>Linos Vandekerckhove</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Reynes</last_name>
    </contact>
    <investigator>
      <last_name>Jacques Reynes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois Raffi</last_name>
    </contact>
    <investigator>
      <last_name>Francois Raffi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Michael Molina</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Michael Molina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karine Lacombe</last_name>
    </contact>
    <investigator>
      <last_name>Karine Lacombe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Katlama</last_name>
    </contact>
    <investigator>
      <last_name>Christine Katlama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juergen Rockstroh</last_name>
    </contact>
    <investigator>
      <last_name>Juergen Rockstroh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goethe University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Stephan</last_name>
    </contact>
    <investigator>
      <last_name>Christoph Stephan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICH Study Center Gmbh &amp; Co. KG</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Jürgen Stellbrink</last_name>
    </contact>
    <investigator>
      <last_name>Hans-Jürgen Stellbrink</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Behrens</last_name>
    </contact>
    <investigator>
      <last_name>Georg Behrens</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mattias Stoll</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Klinikum rechts der Isar der TUM</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Spinner</last_name>
    </contact>
    <investigator>
      <last_name>Christoph Spinner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Mallon</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Mallon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Mallon</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Mallon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Castelli</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Castelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonella d'Arminio Monforte</last_name>
    </contact>
    <investigator>
      <last_name>Antonella d'Arminio Monforte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luigi Sacco Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Rusconi</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Rusconi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonella Castagna</last_name>
    </contact>
    <investigator>
      <last_name>Antonella Castagna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica of Infectious Diseases</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Guaraldi</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Guaraldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INMI Lazzaro Spallanzani, Rome</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Antinori</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Antinori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universatario Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquín Portilla Sogorb</last_name>
    </contact>
    <investigator>
      <last_name>Joaquín Portilla Sogorb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic (Helios Building)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Mallolas</last_name>
    </contact>
    <investigator>
      <last_name>Josep Mallolas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pere Domingo</last_name>
    </contact>
    <investigator>
      <last_name>Pere Domingo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Herbon</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Curran</last_name>
    </contact>
    <investigator>
      <last_name>Adrian Curran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitatrio de Elche</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mar Masia</last_name>
    </contact>
    <investigator>
      <last_name>Mar Masia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Luis Casado Osorio</last_name>
    </contact>
    <investigator>
      <last_name>José Luis Casado Osorio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitatrio La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Perez Valero</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Perez Valero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elbushra Herieka</last_name>
    </contact>
    <investigator>
      <last_name>Elbushra Herieka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Gompels</last_name>
    </contact>
    <investigator>
      <last_name>Mark Gompels</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Minton</last_name>
    </contact>
    <investigator>
      <last_name>Jane Minton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chloe Orkin</last_name>
    </contact>
    <investigator>
      <last_name>Chloe Orkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminister</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessia Dalla Pria</last_name>
    </contact>
    <investigator>
      <last_name>Alessia Dalla Pria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Fox</last_name>
    </contact>
    <investigator>
      <last_name>Julie Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iain Reeves</last_name>
    </contact>
    <investigator>
      <last_name>Iain Reeves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Winston</last_name>
    </contact>
    <investigator>
      <last_name>Alan Winston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Post</last_name>
    </contact>
    <investigator>
      <last_name>Frank Post</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mortimer Market Centre</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Miller</last_name>
    </contact>
    <investigator>
      <last_name>Rob Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Johnson</last_name>
    </contact>
    <investigator>
      <last_name>Margaret Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Hamzah</last_name>
    </contact>
    <investigator>
      <last_name>Lisa Hamzah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Lewisham</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Kegg</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Kegg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Ustianowski</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Ustianowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Rogstad</last_name>
    </contact>
    <investigator>
      <last_name>Karen Rogstad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <reference>
    <citation>DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012 Jun 30;379(9835):2429-2438. doi: 10.1016/S0140-6736(12)60918-0.</citation>
    <PMID>22748590</PMID>
  </reference>
  <reference>
    <citation>Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8.</citation>
    <PMID>23306000</PMID>
  </reference>
  <reference>
    <citation>Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541.</citation>
    <PMID>24195548</PMID>
  </reference>
  <reference>
    <citation>Sax et al. Phase 3 Randomized, Controlled, Clinical Trial of Bictegravir Coformulated With FTC/TAF in a Fixed-Dose Combination vs Dolutegravir + FTC/TAF in Treatment-Naïve HIV-1-Positive Adults: Week 48 Results. 9th IAS Conference on HIV Science; Paris, France; July 23-26, 2017</citation>
  </reference>
  <reference>
    <citation>Gallant et al. A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48. 9th IAS Conference on HIV Science; Paris, France; July 23-26, 2017. MOAB0105LB</citation>
  </reference>
  <reference>
    <citation>Camoni L, Raimondo M, Regine V, Salfa MC, Suligoi B; regional representatives of the HIV Surveillance System. Late presenters among persons with a new HIV diagnosis in Italy, 2010-2011. BMC Public Health. 2013 Mar 27;13:281. doi: 10.1186/1471-2458-13-281.</citation>
    <PMID>23537210</PMID>
  </reference>
  <reference>
    <citation>Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, de Salvador F, Launay O, Martinez V, Partisani M, Pradier C, Rouveix E, Valin N, Grabar S, Costagliola D; French Hospital Database ANRS CO4 cohort. Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):197-203. doi: 10.1097/QAI.0b013e31829cfbfa.</citation>
    <PMID>24047970</PMID>
  </reference>
  <reference>
    <citation>Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, Girardi E, Johnson M, Kirk O, Lundgren J, Mocroft A, D'Arminio Monforte A, Phillips A, Raben D, Rockstroh JK, Sabin C, Sönnerborg A, De Wolf F; European Late Presenter Consensus Working Group. Late presentation of HIV infection: a consensus definition. HIV Med. 2011 Jan;12(1):61-4. doi: 10.1111/j.1468-1293.2010.00857.x.</citation>
    <PMID>20561080</PMID>
  </reference>
  <reference>
    <citation>Raffetti E, Postorino MC, Castelli F, Casari S, Castelnuovo F, Maggiolo F, Di Filippo E, D'Avino A, Gori A, Ladisa N, Di Pietro M, Sighinolfi L, Zacchi F, Torti C. The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. BMC Public Health. 2016 Aug 25;16(1):878. doi: 10.1186/s12889-016-3477-z.</citation>
    <PMID>27557878</PMID>
  </reference>
  <reference>
    <citation>Sobrino-Vegas P, Rodríguez-Urrego J, Berenguer J, Caro-Murillo AM, Blanco JR, Viciana P, Moreno S, Bernardino I, del Amo J; CoRIS. Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. Antivir Ther. 2012;17(1):1-8. doi: 10.3851/IMP1939.</citation>
    <PMID>22267463</PMID>
  </reference>
  <reference>
    <citation>Late presenters working group in COHERE in EuroCoord, Mocroft A, Lundgren J, Antinori A, Monforte Ad, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30070.</citation>
    <PMID>26624933</PMID>
  </reference>
  <reference>
    <citation>Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011 Oct 20;365(16):1492-501. doi: 10.1056/NEJMoa1014181.</citation>
    <PMID>22010915</PMID>
  </reference>
  <reference>
    <citation>Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE; CAMELIA (ANRS 1295–CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1471-81. doi: 10.1056/NEJMoa1013911.</citation>
    <PMID>22010913</PMID>
  </reference>
  <reference>
    <citation>Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E, Komarow L. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575. doi: 10.1371/journal.pone.0005575. Epub 2009 May 18.</citation>
    <PMID>19440326</PMID>
  </reference>
  <reference>
    <citation>Mussini C, Manzardo C, Johnson M, Monforte Ad, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, Miró JM, Sabin C; Late Presenter Investigators. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS. 2008 Nov 30;22(18):2461-9. doi: 10.1097/QAD.0b013e328314b5f1.</citation>
    <PMID>19005269</PMID>
  </reference>
  <reference>
    <citation>Demarest J, Underwood M, St Clair M, Dorey D, Brown D, Zolopa A. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance. AIDS Res Hum Retroviruses. 2018 Apr;34(4):343-346. doi: 10.1089/AID.2017.0184. Epub 2018 Mar 22.</citation>
    <PMID>29444582</PMID>
  </reference>
  <reference>
    <citation>Wijting I et al. Integrase Inhibitors are an Independent Risk Factor for IRIS: An ATHENA Cohort Study. Conference on Retroviruses and Opportunistic Infections. February 2017. Seattle, WA, USA. Abstract 731.</citation>
  </reference>
  <reference>
    <citation>Dutertre M et al. Initiation of ART Based on Integrase Inhibitors Increases the Risk of IRIS. Conference on Retroviruses and Opportunistic Infections. February 2017. Seattle, WA, USA. Abstract 732.</citation>
  </reference>
  <reference>
    <citation>Psichogiou M, Basoulis D, Tsikala-Vafea M, Vlachos S, Kapelios CJ, Daikos GL. Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS). Curr HIV Res. 2017;15(6):405-410. doi: 10.2174/1570162X15666171122155708.</citation>
    <PMID>29173177</PMID>
  </reference>
  <reference>
    <citation>Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials. Curr Opin HIV AIDS. 2018 Mar;13(2):102-111. doi: 10.1097/COH.0000000000000445. Review.</citation>
    <PMID>29278532</PMID>
  </reference>
  <reference>
    <citation>Paredes R, Tzou PL, van Zyl G, Barrow G, Camacho R, Carmona S, Grant PM, Gupta RK, Hamers RL, Harrigan PR, Jordan MR, Kantor R, Katzenstein DA, Kuritzkes DR, Maldarelli F, Otelea D, Wallis CL, Schapiro JM, Shafer RW. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One. 2017 Jul 28;12(7):e0181357. doi: 10.1371/journal.pone.0181357. eCollection 2017.</citation>
    <PMID>28753637</PMID>
  </reference>
  <reference>
    <citation>Levy et al. ANRS 146 - GeSIDA 7211 OPTIMAL phase III trial: maraviroc plus cART in advanced HIV-1-infected individuals. Journal Of The International Aids Society (Vol. 20, Pp. 6-7)</citation>
  </reference>
  <reference>
    <citation>Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM; IMEA 040 DATA Study Group. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). J Antimicrob Chemother. 2016 Aug;71(8):2252-61. doi: 10.1093/jac/dkw103. Epub 2016 Apr 10.</citation>
    <PMID>27068399</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

